COMP <GO>
RGEN vs KYMR // 10Y YIELD & FRED MACRO BETA
Repligen Corporation (NASDAQ) VS. Kymera Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RGEN 6
— KYMR 4
▲ 10Y YIELD & FRED MACRO BETA LEADER: RGEN
LAST: $176.94 (-6.20%) • MKT CAP: $10.03B
macro-sensitivity
1.04
LAST: $126.63 (+3.29%) • MKT CAP: $10.81B
macro-sensitivity
0.95
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. KYMR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | KYMR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | -21.40% | +23.70 | RGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | -2.30% | +3.18 | RGEN | /fcf-yield <GO> |
| Operating Margin | 1.80% | -60.00% | +61.80 | RGEN | /operating-margins <GO> |
| Net Profit Margin | 1.60% | 68.00% | -66.40 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | -16.70% | +13.40 | RGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 26.00 | -16.69 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | RGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 66.0 | -18.00 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.04 | 0.95 | +0.09 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.03B | $10.81B | -$779.4M | KYMR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | KYMR REV | RGEN GROSS % | KYMR GROSS % | RGEN FCF | KYMR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $39.2M | — | 0.0% | $93.9M | -$234.3M |
| FY 2024 | $0 | $47.1M | — | 0.0% | $149.7M | -$207.3M |
| FY 2023 | $0 | $78.6M | — | — | $113.9M | -$106.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
KYMR // BETA 0.95